Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS).
Qure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds overall in September 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback